China introduces promising new obesity drug for local population

China Daily
1794891638000

In a significant development for obesity management, a novel domestically developed drug, Ribupatide, is expected to offer new hope for China's overweight and obese population.

Professor Li Xiaoying from Shanghai-based Zhongshan Hospital, who is also the lead researcher of a study on a novel domestically developed obesity drug, checks on a patient's condition in the hospital ward. (Photo via China Daily)

The medication, which is expected to receive approval by mid-next year, is the country's first homegrown GLP-1/GIP dual agonist and the second of its kind globally. The first, Tirzepatide, was the world's top-selling drug last year.

On Monday, Shanghai-based Zhongshan Hospital Affiliated with Fudan University announced that its clinical study on Ribupatide has been published in the Journal of the American Medical Association. The study is notable for using Chinese-specific obesity diagnostic criteria, focusing on the Chinese population.

Experts highlighted that while international standards diagnose obesity and overweight at a BMI of 30 and 25, respectively, China's thresholds are lower, at 28 and 24. This adjustment accounts for East Asians having higher body fat percentages and more visceral fat accumulation at equivalent BMI levels, increasing the risk of metabolic diseases, such as diabetes, hypertension and hyperlipidemia at earlier stages.

Professor Li Xiaoying, the lead researcher of the study from Zhongshan Hospital's endocrinology department, explained that abdominal obesity is more prevalent among Chinese, indicating higher levels of visceral fat, including liver fat.

Involving 567 participants across 55 research centers nationwide, the Phase III clinical trial demonstrated significant weight loss after 48 weeks of therapy. Participants in the 2 milligrams, 4 mg, and 6 mg dosage groups experienced weight reductions of 10.7 percent, 16.4 percent, and 17.7 percent from baseline, respectively.

"Notably, weight loss in the 4 mg and 6 mg groups had not yet plateaued," said Zhao Lin, another key researcher on the team.

Additionally, the 6 mg group saw an average waist circumference reduction of 14.4 centimeters. "Compared with similar well-known drugs from overseas, Ribupatide achieved greater reductions in weight and waist circumference, alongside improvements in metabolic indicators like blood pressure, lipid levels and uric acid," said Li.

Trial participants averaged 34.4 years old, with a baseline average weight of 93 kg and a BMI of 33.3. Women comprised 54.5 percent of the cohort.

The research team claimed that the once-weekly injection works through dual-target synergy, enhancing weight loss efficacy while minimizing side effects.

With 698 million overweight and obese individuals in China, projected to increase by nearly 20 percent by 2035, the country's need for effective long-term weight management solutions is critical. Experts highlighted that Asian people are particularly sensitive to cardiovascular and metabolic harms caused by obesity, and there is an urgent need for safe and effective new domestic drugs in clinical practice.